Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTX-6016 in healthy subjects and painful diabetic neuropathy
NCT04857957Phase 1Completed
- Sponsor
- Centrexion Therapeutics
- Start
- Apr 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CNTX-6016 in diabetic neuropathy (4 cohorts), sponsored by Centrexion Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events up to 45 days, CNTX-6016 Pharmacokinetics - Cmax and 3 more. Started Apr 2021; status: completed.
02
Drugs
CNTX-6016
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on NCT04857957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857957.